Drugs / cadonilizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07016724 | Aug 2024 → Aug 2026 overdue | esophageal squamous cell carcinoma | The First Affiliated Hospital of Zhengzhou University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cadonilizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07016724 ↗ |
| Modality | Monoclonal antibody | “PD-1/CTLA-4 bi-antibody” NCT07016724 ↗ |